


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: John Babish et al.
Application No.: 10/557,293
Filing Date: December 20, 2006
Docket Number: 068911-0126
Title: Anti-Inflammatory Pharmaceutical Compositions for Reducing
Inflammation and The Treatment or Prevention of Gastric
Toxicity
Examiner: Michael V. Meller
Art Unit: 1655
Confirmation No. 9021

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to Mail Stop: Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, or filed online via EFS-Web to the USPTO, on the date indicated below.

Date: July 27, 2010


Jacqueline Andreu

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REMARKS

The following supplemental terminal disclaimer (TD) are being submitted at the request of Examiner Meller, which was telephonically communicated with the undersign on July 23, 2010.


- TD for U.S. Application No. 11/649,584

No fees are believed to be due in connection with the filing of the supplemental TD partly because MPEP 1490, Examiner's Notes 13.35 and 14.35.01, state that "applicant is not required to pay another disclaimer fee as set forth in 37 CFR 1.20(d) when submitting a replacement or supplemental terminal disclaimer." Examiner Meller has also orally suggested to the undersign that no fees are required when replacement or supplemental TDs are filed at the request of the Examiner.

Nonetheless, the Commissioner is hereby authorize to charge any fees that may be required in connection of with the filing this paper and the terminal disclaims, under 37 C.F.R. 1.20(d), to our Deposit Account 50-1133.

Respectfully submitted,

McDERMOTT WILL & EMERY LLP



Atabak R. Royace, Ph.D.
Registration No. 59,037
McDermott, Will & Emery LLP
28 State Street
Boston, MA 02109 - 1775
Telephone: 617.535.4108
Facsimile: 617.535.3800